Pfizer Expects About $15 Billion in 2021 Sales From COVID Vaccine

Pfizer expects to sell about $15 billion in coronavirus vaccine doses this year, the company announced in releasing its fourth-quarter earnings Tuesday, CNBC writes.

It forecasts revenue this year will be between $59.4 billion and $61.4 billion.

The company also raised its full-year earnings guidance to between $3.10 to $3.20 from $3 to $ 3.10, citing “additional refinements” of its vaccine revenue forecast.

Here’s how Pfizer performed in the fourth quarter compared with what Wall Street expected, according to average estimates compiled by Refinitiv.

Revenue rose 12% to $11.68 billion from $10.44 billion during the same quarter last year — better than analysts expected.

Shares of Pfizer were down 2.6 percent in early trading.

“As a company, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused company,” CEO Albert Bourla said in a press release. “Right away, our ability to move quickly and utilize cutting-edge science to help address the world’s most important medical challenges was put to the test by the COVID-19 pandemic.”

The company’s Covid-19 vaccine, which it’s making with German partner BioNTech, was the first approved for emergency use in the U.S.

Pfizer, like other Covid vaccine makers, has been struggling to meet the demand for shots that hopefully will help bring an end to the pandemic. Pfizer has said it expects to deliver 200 million doses of its two-shot vaccine to the U.S. by July 31. It recently enlisted the help of French drugmaker Sanofi to help produce doses.

The company also said Tuesday it is “prepared to respond” if a Covid variant demonstrates evidence of evading its vaccine. In recent weeks, U.S. health officials, including Dr. Anthony Fauci, have said they are concerned that vaccines currently on the market may not be as effective in guarding against new, more contagious strains of the virus.

Novavax said Thursday its vaccine was only 49% effective against B.1.351, the highly contagious strain found in South Africa. Johnson & Johnson also said its vaccine was less potent against the strain, saying on Friday its one-shot vaccine was 66% effective overall but just 57% effective against the strain in South Africa.

A study conducted by Pfizer found that the new, highly contagious strains found in the U.K. and South Africa had only a small impact on the effectiveness of its vaccine. Still, Pfizer is developing a booster shot to help protect against the new variants. Moderna and Novavax are also developing modified vaccines.

Be the first to comment

Leave a Reply

Your email address will not be published.